Augmentation of myocardial production of 15-epi-lipoxin-A4 by pioglitazone and atorvastatin in the rat

Yochai Birnbaum, Yumei Ye, Yu Lin, Sheldon Y. Freeberg, Shawn Nishi, Juan D. Martinez, Ming He Huang, Barry F. Uretsky, Jose R. Perez-Polo

Research output: Contribution to journalArticle

133 Citations (Scopus)

Abstract

BACKGROUND - Both statins and thiazolidinediones have antiinflammatory properties. However, the exact mechanisms underlying these effects are unknown. We investigated whether atorvastatin (ATV) and pioglitazone (PIO) increase the myocardial content of lipoxin-A4 and 15(R)-epi-lipoxin-A4 (15-epi-LXA4), both arachidonic acid products with strong antiinflammatory properties. METHODS AND RESULTS - In experiment 1, rats received 3-day pretreatment with water; PIO 2, 5, or 10 mg·kg·d; ATV 2, 5, or 10 mg·kg·d; or PIO 10 mg·kg·d+ATV 10 mg·kg·d. In experiment 2, rats received water; PIO 10 mg·kg·d+ATV 10 mg·kg·d; PIO+ATV and valdecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor; PIO+ATV and zileuton, a selective 5-lipoxygenase inhibitor; or zileuton alone. There were 4 rats in each group. Hearts were harvested and analyzed for myocardial lipoxin-A4 and 15-epi-LXA4 levels and for COX-2 and 5-lipoxygenase protein expression. ATV and PIO at 5 and 10 mg·kg·d significantly increased myocardial 15-epi-LXA4 levels compared with the sham-treated group (0.51±0.02 ng/mg). Myocardial 15-epi-LXA4 were significantly higher in the PIO+ATV group (1.29±0.02 ng/mg; P<0.001 versus each other group). Both valdecoxib and zileuton abrogated the PIO+ATV increase in 15-epi-LXA4, whereas zileuton alone had no effect. PIO, ATV, and their combination resulted in a small increase in myocardial lipoxin-A4 levels, which was not statistically significant. ATV alone or in combination with PIO markedly augmented COX-2 expression. PIO had a much smaller effect on COX-2 expression. Myocardial expression of 5-lipoxygenase was not altered by PIO, ATV, or their combination. CONCLUSIONS - Both PIO and ATV increase myocardial levels of 15-epi-LXA4, a mediator with antiinflammatory properties. This finding may explain the antiinflammatory properties of both PIO and ATV.

Original languageEnglish (US)
Pages (from-to)929-935
Number of pages7
JournalCirculation
Volume114
Issue number9
DOIs
StatePublished - Aug 2006

Fingerprint

pioglitazone
zileuton
Anti-Inflammatory Agents
Cyclooxygenase 2
Arachidonate 5-Lipoxygenase
Atorvastatin Calcium
lipoxin A4

Keywords

  • Aspirin
  • Diabetes mellitus
  • Hypercholesterolemia
  • Inflammation
  • Prostaglandins

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Augmentation of myocardial production of 15-epi-lipoxin-A4 by pioglitazone and atorvastatin in the rat. / Birnbaum, Yochai; Ye, Yumei; Lin, Yu; Freeberg, Sheldon Y.; Nishi, Shawn; Martinez, Juan D.; Huang, Ming He; Uretsky, Barry F.; Perez-Polo, Jose R.

In: Circulation, Vol. 114, No. 9, 08.2006, p. 929-935.

Research output: Contribution to journalArticle

Birnbaum, Y, Ye, Y, Lin, Y, Freeberg, SY, Nishi, S, Martinez, JD, Huang, MH, Uretsky, BF & Perez-Polo, JR 2006, 'Augmentation of myocardial production of 15-epi-lipoxin-A4 by pioglitazone and atorvastatin in the rat', Circulation, vol. 114, no. 9, pp. 929-935. https://doi.org/10.1161/CIRCULATIONAHA.106.629907
Birnbaum, Yochai ; Ye, Yumei ; Lin, Yu ; Freeberg, Sheldon Y. ; Nishi, Shawn ; Martinez, Juan D. ; Huang, Ming He ; Uretsky, Barry F. ; Perez-Polo, Jose R. / Augmentation of myocardial production of 15-epi-lipoxin-A4 by pioglitazone and atorvastatin in the rat. In: Circulation. 2006 ; Vol. 114, No. 9. pp. 929-935.
@article{de187a5181c54037a66b5c65fb98f41e,
title = "Augmentation of myocardial production of 15-epi-lipoxin-A4 by pioglitazone and atorvastatin in the rat",
abstract = "BACKGROUND - Both statins and thiazolidinediones have antiinflammatory properties. However, the exact mechanisms underlying these effects are unknown. We investigated whether atorvastatin (ATV) and pioglitazone (PIO) increase the myocardial content of lipoxin-A4 and 15(R)-epi-lipoxin-A4 (15-epi-LXA4), both arachidonic acid products with strong antiinflammatory properties. METHODS AND RESULTS - In experiment 1, rats received 3-day pretreatment with water; PIO 2, 5, or 10 mg·kg·d; ATV 2, 5, or 10 mg·kg·d; or PIO 10 mg·kg·d+ATV 10 mg·kg·d. In experiment 2, rats received water; PIO 10 mg·kg·d+ATV 10 mg·kg·d; PIO+ATV and valdecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor; PIO+ATV and zileuton, a selective 5-lipoxygenase inhibitor; or zileuton alone. There were 4 rats in each group. Hearts were harvested and analyzed for myocardial lipoxin-A4 and 15-epi-LXA4 levels and for COX-2 and 5-lipoxygenase protein expression. ATV and PIO at 5 and 10 mg·kg·d significantly increased myocardial 15-epi-LXA4 levels compared with the sham-treated group (0.51±0.02 ng/mg). Myocardial 15-epi-LXA4 were significantly higher in the PIO+ATV group (1.29±0.02 ng/mg; P<0.001 versus each other group). Both valdecoxib and zileuton abrogated the PIO+ATV increase in 15-epi-LXA4, whereas zileuton alone had no effect. PIO, ATV, and their combination resulted in a small increase in myocardial lipoxin-A4 levels, which was not statistically significant. ATV alone or in combination with PIO markedly augmented COX-2 expression. PIO had a much smaller effect on COX-2 expression. Myocardial expression of 5-lipoxygenase was not altered by PIO, ATV, or their combination. CONCLUSIONS - Both PIO and ATV increase myocardial levels of 15-epi-LXA4, a mediator with antiinflammatory properties. This finding may explain the antiinflammatory properties of both PIO and ATV.",
keywords = "Aspirin, Diabetes mellitus, Hypercholesterolemia, Inflammation, Prostaglandins",
author = "Yochai Birnbaum and Yumei Ye and Yu Lin and Freeberg, {Sheldon Y.} and Shawn Nishi and Martinez, {Juan D.} and Huang, {Ming He} and Uretsky, {Barry F.} and Perez-Polo, {Jose R.}",
year = "2006",
month = "8",
doi = "10.1161/CIRCULATIONAHA.106.629907",
language = "English (US)",
volume = "114",
pages = "929--935",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Augmentation of myocardial production of 15-epi-lipoxin-A4 by pioglitazone and atorvastatin in the rat

AU - Birnbaum, Yochai

AU - Ye, Yumei

AU - Lin, Yu

AU - Freeberg, Sheldon Y.

AU - Nishi, Shawn

AU - Martinez, Juan D.

AU - Huang, Ming He

AU - Uretsky, Barry F.

AU - Perez-Polo, Jose R.

PY - 2006/8

Y1 - 2006/8

N2 - BACKGROUND - Both statins and thiazolidinediones have antiinflammatory properties. However, the exact mechanisms underlying these effects are unknown. We investigated whether atorvastatin (ATV) and pioglitazone (PIO) increase the myocardial content of lipoxin-A4 and 15(R)-epi-lipoxin-A4 (15-epi-LXA4), both arachidonic acid products with strong antiinflammatory properties. METHODS AND RESULTS - In experiment 1, rats received 3-day pretreatment with water; PIO 2, 5, or 10 mg·kg·d; ATV 2, 5, or 10 mg·kg·d; or PIO 10 mg·kg·d+ATV 10 mg·kg·d. In experiment 2, rats received water; PIO 10 mg·kg·d+ATV 10 mg·kg·d; PIO+ATV and valdecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor; PIO+ATV and zileuton, a selective 5-lipoxygenase inhibitor; or zileuton alone. There were 4 rats in each group. Hearts were harvested and analyzed for myocardial lipoxin-A4 and 15-epi-LXA4 levels and for COX-2 and 5-lipoxygenase protein expression. ATV and PIO at 5 and 10 mg·kg·d significantly increased myocardial 15-epi-LXA4 levels compared with the sham-treated group (0.51±0.02 ng/mg). Myocardial 15-epi-LXA4 were significantly higher in the PIO+ATV group (1.29±0.02 ng/mg; P<0.001 versus each other group). Both valdecoxib and zileuton abrogated the PIO+ATV increase in 15-epi-LXA4, whereas zileuton alone had no effect. PIO, ATV, and their combination resulted in a small increase in myocardial lipoxin-A4 levels, which was not statistically significant. ATV alone or in combination with PIO markedly augmented COX-2 expression. PIO had a much smaller effect on COX-2 expression. Myocardial expression of 5-lipoxygenase was not altered by PIO, ATV, or their combination. CONCLUSIONS - Both PIO and ATV increase myocardial levels of 15-epi-LXA4, a mediator with antiinflammatory properties. This finding may explain the antiinflammatory properties of both PIO and ATV.

AB - BACKGROUND - Both statins and thiazolidinediones have antiinflammatory properties. However, the exact mechanisms underlying these effects are unknown. We investigated whether atorvastatin (ATV) and pioglitazone (PIO) increase the myocardial content of lipoxin-A4 and 15(R)-epi-lipoxin-A4 (15-epi-LXA4), both arachidonic acid products with strong antiinflammatory properties. METHODS AND RESULTS - In experiment 1, rats received 3-day pretreatment with water; PIO 2, 5, or 10 mg·kg·d; ATV 2, 5, or 10 mg·kg·d; or PIO 10 mg·kg·d+ATV 10 mg·kg·d. In experiment 2, rats received water; PIO 10 mg·kg·d+ATV 10 mg·kg·d; PIO+ATV and valdecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor; PIO+ATV and zileuton, a selective 5-lipoxygenase inhibitor; or zileuton alone. There were 4 rats in each group. Hearts were harvested and analyzed for myocardial lipoxin-A4 and 15-epi-LXA4 levels and for COX-2 and 5-lipoxygenase protein expression. ATV and PIO at 5 and 10 mg·kg·d significantly increased myocardial 15-epi-LXA4 levels compared with the sham-treated group (0.51±0.02 ng/mg). Myocardial 15-epi-LXA4 were significantly higher in the PIO+ATV group (1.29±0.02 ng/mg; P<0.001 versus each other group). Both valdecoxib and zileuton abrogated the PIO+ATV increase in 15-epi-LXA4, whereas zileuton alone had no effect. PIO, ATV, and their combination resulted in a small increase in myocardial lipoxin-A4 levels, which was not statistically significant. ATV alone or in combination with PIO markedly augmented COX-2 expression. PIO had a much smaller effect on COX-2 expression. Myocardial expression of 5-lipoxygenase was not altered by PIO, ATV, or their combination. CONCLUSIONS - Both PIO and ATV increase myocardial levels of 15-epi-LXA4, a mediator with antiinflammatory properties. This finding may explain the antiinflammatory properties of both PIO and ATV.

KW - Aspirin

KW - Diabetes mellitus

KW - Hypercholesterolemia

KW - Inflammation

KW - Prostaglandins

UR - http://www.scopus.com/inward/record.url?scp=33748363508&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748363508&partnerID=8YFLogxK

U2 - 10.1161/CIRCULATIONAHA.106.629907

DO - 10.1161/CIRCULATIONAHA.106.629907

M3 - Article

C2 - 16908763

AN - SCOPUS:33748363508

VL - 114

SP - 929

EP - 935

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 9

ER -